'Strange New Worlds' Season 3, Episode 1 Ending Sets Up a Classic 'Star Trek' Smackdown
But, as the episode makes clear, the Gorn aren't totally defeated, just sidelined. And with one specific line, Strange New Worlds is sneakily setting the table for a classic 1967 Star Trek episode that, technically, takes place in this show's future. Spoilers ahead.
Strange New Worlds Season 3, Episode 1 Ending, Explained
Because the Gorn communicate through light, Uhura (Celia Rose Gooding) and Number One (Rebecca Romijn) figure out that large solar flares can tell all of the Gorn to either wake up and start hunting or, crucially, to go to sleep. The fix? If Scotty (Martin Quinn) can make the Enterprise appear like an actual sun, the Gorn's sleep cycle will be triggered.
In classic Trek style, Scotty gives it all he's got, and it works, just barely. The Gorn invasion of the Federation is halted, and Captain Pike says, "I can't help but wonder if we didn't just create a problem for someone else to solve later.'
But what did he mean by that?
Strange New Worlds Just Set Up "Arena"
At this point, Strange New Worlds Season 3 is taking place roughly in the year 2259. This puts it about six years, give or take, before the events of Star Trek: The Original Series. Yes, the technology looks way better in SNW than it did in the classic show, but if you squint a little, it works.
And, if you don't worry too much about how fierce the Gorn look in this show, then you'll probably be able to reconcile that idea with the green-rubber Gorn from the 1967 episode "Arena." In that episode, Captain Kirk (William Shatner) fought a Gorn by himself, in a kind of test to prove whether or not humans were both resourceful, but also kind.
In terms of the timeline, Captain Kirk is Captain Pike's successor, and in Strange New Worlds, is played by Paul Wesley, who is not yet a Starfleet captain. So, even though Pike doesn't know it yet, the problem that someone has to solve later will be solved by James T. Kirk in "Arena."
Strange New Worlds debuted with two new episodes in Season 3. There will be eight more after that, each dropping weekly on Thursdays. But, if you want a sequel to Season 3, Episode 1, then all you have to do is watch Star Trek: The Original Series, Season 1, Episode 19, "Arena" and get ready to watch Captain Kirk wrestle in the sand with an incredible lizard man.'Strange New Worlds' Season 3, Episode 1 Ending Sets Up a Classic 'Star Trek' Smackdown first appeared on Men's Journal on Jul 17, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search
Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder is now available on BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations—enhancing the user experience and freeing up more time for patient care. Laboratory testing plays a critical role in healthcare, informing nearly 70% of clinical decisions and often serving as the first step in diagnosing and managing patient conditions. Yet research shows providers spend more than three hours a day on responsibilities including documentation and test ordering—time that could be spent with patients. According to a recent American Medical Association (AMA) survey, 57% of physicians view addressing administrative burden through automation as the greatest opportunity for AI in healthcare. "Clinicians are under increasing pressure to do more with less," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "Test Finder is designed to ease that burden by providing a faster, more intuitive way to navigate complex test menus, conduct research and identify the right tests, so clinicians can focus on what matters most: their patients." Key Features of Labcorp's Test FinderNow available on Test Finder was developed using Amazon Bedrock and large language model (LLM) technology. The tool enables providers to ask questions or describe conditions in plain language and receive a detailed list of suggested tests and descriptions based on their input. Additional benefits include: Access to thousands of lab tests across key therapeutic areas, including oncology, women's health, neurology, autoimmune disease and more Faster, more efficient navigation that reduces time spent on test selection Available 24/7 on "Labcorp's AI implementation underscores the transformative power of responsible generative AI in healthcare, setting a new industry standard for clinical workflow optimization," said Dr. Rowland Illing, global chief medical officer at AWS. "By leveraging AWS' enterprise-grade AI infrastructure and HIPAA-compliant security controls, Labcorp is revolutionizing how healthcare providers access comprehensive diagnostic information, enabling faster decisions that can directly impact patient care outcomes." "Test Finder is a powerful example of how we're using technology to simplify complexity," said Bola Oyegunwa, Ph.D., Labcorp's chief information and technology officer. "By integrating generative AI, we're not only improving the provider experience, we're laying the foundation for smarter, more connected healthcare solutions that scale with the needs of our customers." Labcorp anticipates sharing additional updates and announcements related to Test Finder in the coming weeks. For more information, visit About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at View original content to download multimedia: SOURCE Labcorp
Yahoo
21 minutes ago
- Yahoo
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relationsir@ 410-0266 LifeSci Advisors, Mike Moyermmoyer@ 308-4306 Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@ 234-3889Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Aldevron Launches New Innovation Center in Waltham, MA
Strategic expansion places Aldevron at the heart of the Boston biotech corridor, fueling next-generation breakthroughs in genomic medicine FARGO, N.D. & WALTHAM, Mass., July 30, 2025--(BUSINESS WIRE)--Aldevron, a Danaher company, and a global leader in the production of DNA, RNA and protein in the genomic medicine space, today announced the planned opening of its new Innovation Center in Waltham, Massachusetts. The milestone marks a bold step in Aldevron's mission to accelerate innovation in genomic medicines while deepening its presence in one of the world's most dynamic biotech hubs. The new Waltham site is designed to fast-track advancements in the manufacture of DNA, RNA and proteins for advanced therapies, expanding Aldevron's capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By establishing a base in the Boston area, Aldevron is positioning itself at the epicenter of biotech innovation—enabling closer collaboration with clients, faster project timelines and enhanced support for the development of advanced therapies. "Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery," said Venkata Indurthi, Chief Scientific Officer at Aldevron. "This Innovation Center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech." The Waltham Innovation Center will complement Aldevron's established scientific teams in Fargo, ND, and Madison, WI, and will serve as a catalyst for recruiting top talent from Boston's vibrant biotech community. "Our recent role in the groundbreaking 'Baby KJ' CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation," said Jennifer Meade, President of Aldevron. "As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships and greater support for the scientists shaping the future of medicine." About Aldevron Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron's expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world's first mRNA-based personalized CRISPR therapy. With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe. To learn more about how Aldevron is advancing biological science, visit and follow the company on LinkedIn, Facebook and YouTube. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at View source version on Contacts Media Contact: Ellen ShaferSenior Director of (701) 219-0333
